From trials to statistical insights: Bortezomib's story in childhood T‐cell lymphoid malignancies

Documenti analoghi

• New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
  di: Maria Anele Romeo, et al.
  Pubblicazione: (2024)
• Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
  di: Lucio N. Gordan, et al.
  Pubblicazione: (2025)
• Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy
  di: Enrico Grande, et al.
  Pubblicazione: (2024)
• Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
  di: Mohammed Zuber, et al.
  Pubblicazione: (2024)
• 739 | ADDRESSING HYPERCALCEMIA IN ADULT T‐CELL LEUKEMIA/LYMPHOMA
  di: M. Srinivasan, et al.
  Pubblicazione: (2025)